However, experts warn that people should not stop taking their blood pressure medication on their own. High blood pressure is ...

An IOL-mounted sustained bimatoprost delivery system demonstrated a reduction in IOP in two clinical trials of patients with glaucoma or ocular hypertension, according to a press release from SpyGlass ...

It's one of the most common causes of vision loss, and one of the easiest to overlook. Glaucoma symptoms develop so gradually ...

The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study finds.

Background/Aims Major age-related ocular diseases (ARODs)—glaucoma, degeneration of macula and posterior pole (DMPP) and ...

Bentham Science’s new release, Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma – Ocular Hypertension, compiles rigorously tested experimental methods aimed at advancing ...

Developed by Glaukos, the iDose TR (travoprost intraocular implant) 75 mcg is a new, FDA-approved treatment that is designed ...

We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These ...

Founded to accelerate innovation in glaucoma treatment, Glaucoma 360 is GRF’s signature event and one of the vision community’s most anticipated annual gatherings. The three-day program features a ...

SpyGlass Pharma has released positive data from 2 trials of its lead candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL ...

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma ...

BOZEMAN, MT – November 04, 2025 – PRESSADVANTAGE – Glaucoma continues to be one of the most significant causes of vision loss across the country, often developing slowly and without obvious warning ...